Table 3.
Antibiotic non-susceptibility patterns of 70 Staphylococcus aureus isolates from clinical samples
| Non-susceptibility pattern a |
No. of isolates in
|
|||
|---|---|---|---|---|
|
MRSA
b
N= 12 (%) |
MSSA
c
N= 58 (%) |
Integr o n I-positive isolates N= 6 (%) |
Integron I-negative isolates
N= 64 (%) |
|
| P | 0 | 27(46.5) | 3 (50) | 24 (37.5) |
| P,CI | 0 | 1(1.7) | 0 | 1 (1.6) |
| P,E | 0 | 10(17.2) | 1(16.7) | 9 (14.1) |
| TE,P | 0 | 1(1.7) | 0 | 1(1.6) |
| P,CX (MDR)b | 1(8.3) | 0 | 1 (16.7) | 0 |
| P,E,VA (MDR) | 0 | 1 (1.7) | 0 | 1(1.6) |
| TE,P,E (MDR) | 0 | 1(1.7) | 0 | 1(1.6) |
| P,GM,E (MDR) | 0 | 1(1.7) | 0 | 1(1.6) |
| P,E,CC (MDR) | 0 | 3 (5.2) | 0 | 3 (4.7) |
| P, E,CI,VA (MDR) | 0 | 1 (1.7) | 0 | 1(1.6) |
| P,E,CC,CI (MDR) | 0 | 2 (3.4) | 0 | 2 (3.1) |
| TE,P,CX,E (MDR) | 1(8.3) | 0 | 0 | 1(1.6) |
| P,GM,CX,E,CI (MDR) | 1(8.3) | 0 | 0 | 1(1.6) |
| TE,P,E,CC,CI (MDR) | 0 | 6 (10.3) | 0 | 6 (9.4) |
| TE,P,E,CC,CI,VA (MDR) | 0 | 1 (1.7) | 0 | 1(1.6) |
| P,GM,CX,E,CC,CI (MDR) | 1(8.3) | 0 | 0 | 1(1.6) |
| TE,P,CX,E,CC,CI (MDR) | 2(16.7) | 0 | 0 | 2(3.1) |
| TE,P,GM,CX,E,CC,CI (MDR) | 3(25) | 0 | 0 | 3(4.7) |
| TS,TE,P,GM,CX,E,CC,CI (MDR) | 2(16.7) | 0 | 1(16.7) | 1(1.6) |
| TS,TE,P,GM,CX,E,CC,CI,VA (MDR) | 1(8.3) | 0 | 0 | 1(1.6) |
| All susceptible | 0 | 3 (5.2) | 0 | 3(4.7) |
a TS: trimethoprim-sulfamethoxazole; TE: tetracycline; P: penicillin; LZ: linezolid; GM: gentamicin; CX: cefoxitin; E: erythromycin; CC: clindamycin; CI: ciprofloxacin; VA: vancomycin
b MDR: multidrug-resistant (non-susceptible strains to at least 1 agent in 3 or more antimicrobial categories and an MRSA is considered MDR (19)